Market Intelligence, Clinical Progress, and High-Purity Reagents for Central Nervous System and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for S1PR5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | S1PR5 Lentivirus Premade Particles. High titer, Sequence Verified. For stable cell line construction. | View S1PR5 Products |
| Gene Delivery | S1PR5 Promise-ORF Lentivirus. Codon-optimized ORF for stable cell line generation. High titer (>10^8 TU/mL). | View S1PR5 Products |
| Cell Line Tool | S1PR5 Stable Cell Line Support. HEK293 or CHO-K1 background. Puromycin selectable. For calcium flux and internalization assays. | View S1PR5 Products |
| Benchmark Ab | Anti-S1PR5 (Sequence of Biosimilar / Siponimod Competition). Recombinant positive control for flow cytometry and binding studies. | View S1PR5 Products |
| Validator | S1PR5 siRNA Set. Validated knockdown sequences for specificity confirmation. Endotoxin controlled. | View S1PR5 Products |
| Related Target A | S1PR1. Primary co-target for multiple sclerosis therapeutics. Co-modulation with S1PR5. | View S1PR1 Products |
| Related Target B | S1PR3. Crucial counter-screening target to avoid cardiotoxicity. Vascular and cardiac safety liability. | View S1PR3 Products |
| Related Target C | SPHK1. Sphingosine kinase 1. Upstream enzyme controlling S1P ligand availability. Synergistic pathway node. | View SPHK1 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Integrity | Full-length ORF Lentivirus preserves 7-TM topology and coupling to Gαi/o proteins. HEK293 expressed for native glycosylation. Lentivirus-mediated stable cell lines maintain native multi-pass GPCR folding. |
| Cross-species Cyno/Mouse/Human Translation | Ortholog ORF lentiviruses available (Human, Cyno, Mouse) with >95% sequence identity. Critical for preclinical safety assessment. |
| Internalization Mechanism Validation | Stable cell lines compatible with Incucyte® and high-content imaging for S1P-induced receptor internalization quantification. |
| Off-target Selectivity Screening | S1PR1, S1PR2, S1PR3 subfamily cell lines available for rigorous selectivity screening. Endotoxin <0.1 EU/mL to prevent macrophage activation artifacts. |
| Knockdown Specificity Control | Validated siRNA included for receptor-specificity confirmation in competition binding assays. |
Live S1PR5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Neuroimmunology Research
- Resistance and Selectivity Mechanisms
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for S1PR5-targeted therapeutics has evolved beyond broad-spectrum S1P modulators toward selective S1PR1/S1PR5 dual agonists. Following the clinical validation of Siponimod (Novartis) and Ozanimod (Bristol Myers Squibb) in multiple sclerosis, the next wave of R&D is targeting neuroprotective mechanisms in oligodendrocytes and precision immunotherapy for inflammatory bowel disease. Differentiation now focuses on minimizing S1PR3-mediated cardiac liabilities while maximizing CNS penetration for neurodegenerative indications. First-generation therapies have established safety benchmarks; future efforts will prioritize high selectivity and improved safety profiles.
Key Mutations and Research Tools
Notable variants in the S1PR5 gene include dbSNP:rs35483143 (UniProt VAR_033466). This naturally occurring mutation is relevant for population genetics studies and may influence receptor pharmacology. TarMart offers custom mutagenesis services to generate mutant S1PR5 reagents for functional characterization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| S1P Receptor Modulator (Small Molecule) | Novartis, Bristol Myers Squibb, Arena/Pfizer | Secondary Progressive MS, Ulcerative Colitis, RRMS | Cell-based internalization assay (Need stable S1PR5-expressing lines with Gαi coupling) |
| Selective S1PR5 Agonist | Venturis Pharma, Early Biotech | Neurodegeneration, Oligodendrocyte Remyelination | Calcium flux and cAMP inhibition assays (High purity, low background cell lines) |
| Antibody/Alternative Scaffold | Emerging Biotechs, Preclinical/Academic | Neuroinflammation, Autoimmune Lymphopenia | Flow cytometry binding validation (Need native conformation lentivirus-transduced cells) |
| PROTACs / Degraders | Academic/Early Pharma | Refractory Autoimmune | Degradation Validation (Need specific antibodies/siRNA) |
| SPHK Inhibitor (Upstream) | Merck KGaA, Latitude Pharmaceuticals | Oncology, Fibrosis | Pathway crosstalk studies (S1PR5 knockdown/siRNA for target validation) |